Minerva Neurosciences, Inc

Contributing Author

Recent Articles by Minerva Neurosciences, Inc

Jan-26	Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 NERV GlobeNewswire
Nov-19	Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors NERV GlobeNewswire
Nov-05	Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates NERV GlobeNewswire
Oct-21	Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved NERV +140.98% GlobeNewswire
Aug-14	Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results NERV +25.35% NERV GlobeNewswire
May-13	Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates NERV GlobeNewswire